PEG & ADCs
- FDA Approved Antibody-Drug Conjugates (ADCs) Up To 2023
- Clinical Development of ADC Drugs Targeting TROP-2
- Antibody-Drug Conjugates With Dual Payloads Against Heterogeneous Tumors
- Claudin18.2 Targeted Therapies In Cancer
- What Are ADC Linkers: Cleavable vs. Non-Cleavable Linkers
- The Rise of the TROP2-Directed ADCs for Solid Tumors
- Antibody-drug Conjugates (ADCs) - Approvals & Clinical Trails
- FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx)
- Novel FRα-targeting Antibody-drug Conjugates (ADCs)
- Key To The Successful Design of ADC Drugs